ERA-NET for Translational Cancer Research (TRANSCAN-3)- Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy.
- Entidad convocante:
- European Commission
- Projectes de recerca
- Plazo interno:
- Plazo real:
- Veure requisits
Hard-to-treat-cancers (HTTC), i.e. those characterized by very poor prognosis (5-year survival rate<25%) and for which survival has not improved significantly over the last decades. The call aims to foster translational research tackling current clinical challenges, which include the inadequacy of standard diagnostic tools or established early detection methods in the general population, but also the inefficacy of available treatment options, due to intrinsic resistance and/or ineffective drug delivery.
Hard-to-treat cancers: Glioblastoma, Pancreas, Pleural mesothelioma, Gallbladder, Oesophagus, Liver and bile ducts, Lung/bronchus
Proposals will have to cover at least one of the undermentioned aims:
Aim 1: Identification/validation of novel early diagnostic approaches.
Aim 2: Identification/validation of novel therapeutic approaches.
Aim 3: Development of novel drug delivery strategies.
Partners may belong to one of the following categories:
- Academic research groups (from universities or other higher education or research institutions).
- Clinical/public health sector research groups (from hospitals/public health and/or other health care settings and health organisations).
- Private sector/Enterprise research groups (depending on national/regional eligibility rules), with particular emphasis on small and mediumsized enterprises.
Transnational research consortia involving a minimum of three and a maximum of six research groups are eligible to apply.
Each consortium must involve at least one basic or pre-clinical research team and one clinical team. Consortia may also involve other teams with specialised skills and know-how or expertise.
A consortium should not involve more than two research groups from one country.
The maximum number of partners can be increased to 7 in the full proposal stage as a consequence of the widening process aimed at including one team from underrepresented countries/regions ( Hungary, Latvia and Slovakia).
Eligibility is determined by national/regional eligibility rules and funding agencies will only fund partners from their own country/region. A consortium may include one research group (included in the maximum number) with own funding from a country/region not partnering in the Call.
Participating countries: Austria, Belgium, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Portugal, Romania, Slovak Republic, Spain, Taiwan.
For Spanish entities requesting funding from ISCIII: if partners: 175,000; if coordinator: 250,000. Indirect costs of 20% included. The total budget of the Instituto de Salud Carlos III for the call is 1M€, with which it is intend to finance between 4 and 6 groups.
In case of interest please click on "m'interessa" and we will contact you.